FDA expands uses of Vyvanse to treat binge-eating disorder
The FDA has expanded the approved uses of Vyvanse (lisdexamfetamine dimesylate) to treat binge-eating disorder in adults. The drug is the first FDA-approved medication to treat this condition. Vyvanse is marketed by Shire U.S., based in Wayne, Pennsylvania. January 30, 2015